Exploring the patient experience in polymyalgia rheumatica.
Experience
Patient satisfaction
Polymyalgia rheumatica
Qualitative research
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
28
07
2023
accepted:
10
10
2023
revised:
06
10
2023
medline:
13
11
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
Despite being the most common inflammatory rheumatic disease in the elderly (Partington et al., Ann Rheum Dis 77(12):1750-175, 2018), few studies to date have examined the patient experience of polymyalgia rheumatica (PMR). Our study explored patient perspectives in PMR by means of a survey and semi-structured group interviews. The results from this study highlight key aspects of the patient experience in PMR, including delays to diagnosis, complex attitudes toward glucocorticoid therapy, and a desire for alternate treatment strategies. Future trials should look to include physical function as a measured outcome. Finally, our results call attention to the chronicity of PMR symptoms, challenging the paradigm of PMR as a self-limiting condition.
Identifiants
pubmed: 37861872
doi: 10.1007/s10067-023-06794-3
pii: 10.1007/s10067-023-06794-3
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
3421-3422Informations de copyright
© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Partington R et al (2018) Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis 77(12):1750–1756. https://doi.org/10.1136/annrheumdis-2018-213883
doi: 10.1136/annrheumdis-2018-213883
pubmed: 30297332
Twohig H et al (2015) “I suddenly felt I’d aged”: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns 98(5):645–650. https://doi.org/10.1016/j.pec.2014.12.013
doi: 10.1016/j.pec.2014.12.013
pubmed: 25638304
Muller S et al (2018) Support available for and perceived priorities of people with polymyalgia rheumatica and giant cell arteritis: results of the PMRGCAuk members’ survey 2017. Clin Rheumatol 37(12):3411–3418. https://doi.org/10.1007/s10067-018-4220-1
doi: 10.1007/s10067-018-4220-1
Morton C et al (2019) Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey. Clin Rheumatol 38(6):1767–1772. https://doi.org/10.1007/s10067-018-04405-0
doi: 10.1007/s10067-018-04405-0
pubmed: 30617599
pmcid: 6544756
Hoon E et al (2019) A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis. Open Access Rheumatol 11:189–198. https://doi.org/10.2147/OARRR.S213964
doi: 10.2147/OARRR.S213964
pubmed: 31695526
pmcid: 6718238
Twohig H et al (2021) Outcomes measured in polymyalgia rheumatica and measurement properties of instruments considered for the OMERACT core outcome set: a systematic review. J Rheumatol 48(6):883–893. https://doi.org/10.3899/jrheum.200248
doi: 10.3899/jrheum.200248
pubmed: 32739892